Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Insmed nets $378mm via FOPO

Executive Summary

Respiratory disease-focused Insmed Inc. netted $378mm through a follow-on public offering of 14.12mm common shares (including the overallotment) priced at $28.50 each. The company will use the funds for ongoing clinical trials of its Phase III amikacin liposome inhalation suspension for refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex and for activities tied to regulatory approval and commercialization, initially in the US and later in Japan and other countries. Additional funds will support product manufacturing and to continue developing Phase II INS1007 for non-cystic fibrosis bronchiectasis.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies